B-type natriuretic peptide-guided therapy for heart failure (HF):a systematic review and meta-analysis of individual participant data (IPD) and aggregate data by Pufulete, Maria et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
B-type natriuretic peptide-guided therapy for heart failure (HF)
Pufulete, Maria; Maishman, Rachel; Dabner, Lucy; Higgins, Julian P T; Rogers, Chris A;
Dayer, Mark; MacLeod, John; Purdy, Sarah; Hollingworth, William; Schou, Morten; Anguita-
Sanchez, Manuel; Karlström, Patric; Shochat, Michael Kleiner; McDonagh, Theresa;
Nightingale, Angus K; Reeves, Barnaby C
Published in:
Systematic Reviews
DOI:
10.1186/s13643-018-0776-8
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Pufulete, M., Maishman, R., Dabner, L., Higgins, J. P. T., Rogers, C. A., Dayer, M., ... Reeves, B. C. (2018). B-
type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual
participant data (IPD) and aggregate data. Systematic Reviews, 7, [112]. https://doi.org/10.1186/s13643-018-
0776-8
Download date: 03. Feb. 2020
RESEARCH Open Access
B-type natriuretic peptide-guided therapy
for heart failure (HF): a systematic review
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Abstract
Background: We estimated the effectiveness of serial B-type natriuretic peptide (BNP) blood testing to guide
up-titration of medication compared with symptom-guided up-titration of medication in patients with heart
failure (HF).
Methods: Systematic review and meta-analysis of randomised controlled trials (RCTs). We searched: MEDLINE
(Ovid) 1950 to 9/06/2016; Embase (Ovid), 1980 to 2016 week 23; the Cochrane Library; ISI Web of Science
(Citations Index and Conference Proceedings). The primary outcome was all-cause mortality; secondary
outcomes were death related to HF, cardiovascular death, all-cause hospital admission, hospital admission for
HF, adverse events, and quality of life. IPD were sought from all RCTs identified. Random-effects meta-analyses
(two-stage) were used to estimate hazard ratios (HR) and confidence intervals (CIs) across RCTs, including HR
estimates from published reports of studies that did not provide IPD. We estimated treatment-by-covariate
interactions for age, gender, New York Heart Association (NYHA) class, HF type; diabetes status and baseline
BNP subgroups. Dichotomous outcomes were analysed using random-effects odds ratio (OR) with 95% CI.
Results: We identified 14 eligible RCTs, five providing IPD. BNP-guided therapy reduced the hazard of hospital
admission for HF by 19% (13 RCTs, HR 0.81, 95% CI 0.68 to 0.98) but not all-cause mortality (13 RCTs; HR 0.87,
95% CI 0.75 to 1.01) or cardiovascular mortality (5 RCTs; OR 0.88, 95% CI 0.67 to 1.16). For all-cause mortality,
there was a significant interaction between treatment strategy and age (p = 0.034, 11 RCTs; HR 0.70, 95% CI
0.53–0.92, patients < 75 years old and HR 1.07, 95% CI 0.84–1.37, patients ≥ 75 years old); ejection fraction
(p = 0.026, 11 RCTs; HR 0.84, 95% CI 0.71–0.99, patients with heart failure with reduced ejection fraction
(HFrEF); and HR 1.33, 95% CI 0.83–2.11, patients with heart failure with preserved ejection fraction (HFpEF)).
Adverse events were significantly more frequent with BNP-guided therapy vs. symptom-guided therapy (5
RCTs; OR 1.29, 95% CI 1.04 to 1.60).
Conclusion: BNP-guided therapy did not reduce mortality but reduced HF hospitalisation. The overall quality
of the evidence varied from low to very low. The relevance of these findings to unselected patients,
particularly those managed by community generalists, are unclear.
Systematic review registration: PROSPERO CRD42013005335
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Background
Heart failure (HF) affects over 500,000 people in the UK.
Despite advances in medical treatment and evidence-based
guidelines, patients continue to have high morbidity and
poor life expectancy [1]. Many patients are not
treated according to guidelines and do not receive op-
timal doses of available medications [2]. Clinicians
sometimes find it difficult to recognise the early
stages of worsening HF and are reluctant to increase
doses of medications because of concerns about side
effects such as renal failure and hypotension. Re-
cently, biomarkers such as natriuretic peptides (B-type
natriuretic peptide, BNP; or the N-terminal part of
the precursor peptide of BNP, N-terminal pro-B-type
natriuretic peptide, NT-proBNP, collectively referred
to here as BNP), have been used as a more objective
means of assessing HF severity and to prompt more
appropriate titration of HF therapies.
Several randomised controlled trials (RCTs) have
assessed whether using serial BNP tests to guide
up-titration of medication improves clinical outcomes
compared with symptom-guided therapy. The RCTs were
heterogeneous in design. Most used a BNP-lowering
strategy, where a BNP target was set (a single target for all
patients or an individualised target) and HF medications
were intensified to lower or maintain BNP at the
pre-specified target. A few used a BNP-monitoring
strategy, where the treating clinician was allowed to inten-
sify HF medications using serial BNP measurements but
no BNP target was set. Data from RCTs using a
BNP-lowering strategy have been pooled in six aggregate
data meta-analyses [3–8], one individual participant data
(IPD) meta-analysis [9] All of these analyses showed that
patients in the BNP-lowering group had better outcomes.
We conducted a systematic review and meta-analysis
of IPD and aggregate data including all RCTs, regardless
of BNP-guiding strategy [10]. Specific objectives were to
estimate the effect of BNP-guided therapy on clinical
outcomes; to estimate the extent of effect modification
for key outcomes in specific subgroups; and to quantify
the extent to which improved outcomes are explained by
up-titration of medication and/or reduction in BNP
levels. In this paper, we present an update of our
meta-analysis to include data from the Guide-IT RCT
[11], the largest RCT to date (894 patients), which
planned to recruit 1100 patients but was terminated
early because of futility.
Methods
The protocol for the meta-analysis has been published pre-
viously [12]. The study population was all patients aged
over > 18 years who were being treated for HF in primary
or secondary care BNP-guided therapy or symptom-guided
therapy. The primary outcome was all-cause mortality;
secondary outcomes were death related to HF, cardiovascu-
lar death, all-cause hospitalisation, HF hospitalisation, ad-
verse events, and quality of life.
Search methods for identification of studies
The search strategy is shown in Additional file 1:
Appendix 1. We searched the following electronic da-
tabases: MEDLINE (Ovid) 1950 to 6 September 2016;
Embase (Ovid), 1980 to 2016, week 23; the Cochrane
Library; ISI Web of Science (Citations Index and
Conference Proceedings). We also searched the World
Health Organization International Clinical Trials Registry
Platform (WHO ICTRP; http://apps.who.int/trialsearch/)
and Current Controlled Trials (http://www.isrctn.com/) to
identify trials in progress. We reviewed reference lists of all
full-text papers and also searched grey literature (http://
www.opengrey.eu/ and Google Scholar).
Study selection
Two review authors (MP and LD) independently triaged
the titles and abstracts identified by the search and
assessed the full text of all studies identified as relevant
to the review. Differences in assessment by were re-
solved through discussion with a third author (RM). No
language restriction was applied.
Establishing the collaboration
Corresponding authors of eligible RCTs were invited
to join the collaboration and were sent the IPD
meta-analysis protocol with a cover letter explaining
the study.
Quality assessment
Two review authors (MP and LD) independently assessed
the risk of bias (in accordance with recent Cochrane Col-
laboration guidelines [13]) in each included RCT. For
blinding and incomplete outcome data, risk of bias was
assessed separately for pre-specified outcome domains
(all-cause mortality, cause-specific mortality, adverse
events, and quality of life). For incomplete outcome data
and selective outcome reporting, risk of bias was assessed
only in RCTs that contributed aggregate data.
Data collection and checking
IPD were collated into a single database. All datasets
were checked for consistency against the original publi-
cation reports and discrepancies were discussed and
clarified with authors via email. Where authors did not
provide clarification, we documented assumptions that
were made regarding the data.
Statistical analysis
Meta-analysis was carried out if > 2 RCTs reported data on
the outcome of interest. All analyses were performed on an
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intention-to-treat basis. Hazard ratios (HR) were estimated
using Cox regression modelling for each RCT. For RCTs
that did not provide IPD, HR estimates from published re-
ports [14] were combined with HR estimates derived from
the IPD. The HRs were combined across RCTs using
random-effects meta-analysis (two stage model results using
the generic inverse-variance method) [15], and consistency
of findings across studies was assessed using the I2 test stat-
istic. Fixed-effects meta-analysis was also performed as a
secondary analysis. Subgroup effects were determined by es-
timating treatment-by-covariate interaction terms for each
RCT and combining the HRs across RCTs as for the main
effects [16]. Covariates defining subgroups were age (< 75
vs. ≥ 75 years); gender; New York Heart Association
(NYHA) class (class I/II vs class III/IV); type of HF (reduced
ejection fraction, HFrEF, vs. preserved ejection fraction,
HFpEF, based on LVEF, < 40% in studies providing IPD and
< 45% in studies providing aggregate data); diabetes status,
BNP level (≤ vs. >median at baseline across all RCT partici-
pants, with separate medians calculated for RCTs that re-
ported BNP and NTpro-BNP; cause of HF (ischaemic/
non-ischaemic); previous atrial fibrillation; body mass index;
systolic blood pressure. The age cut-off was chosen for
consistency with other studies in elderly HF populations
and to allow easy comparison with the meta-analysis by
Troughton et al. [9]. For the LVEF cut-off, we used the
lower limit of normal LVEF (40%) used in clinical practice.
This threshold of 40% was pre-specified by the study au-
thors, although for the aggregate data studies, we had to use
the cut-off of 45% specified by the researchers of the exist-
ing IPD meta-analysis [17]. As for the main analysis, HR es-
timates from published reports [14] were combined with
HR estimates derived from the IPD. We calculated interac-
tions when these were not reported from subgroup-specific
HRs with 95% confidence intervals (CI) from studies using
aggregate data and pooled them with interactions from add-
itional RCTs which had contributed IPD for this study. For
cardiovascular mortality and adverse events, we calculated
odds ratios (OR) and 95% CI in each trial and pooled these
across RCTs using random effects meta-analyses. We
assessed the certainty of the evidence across each outcome
measure using the GRADE approach (risk of bias,
consistency of effect, imprecision, indirectness, and publica-
tion bias) (http://www.gradeworkinggroup.org/.).
The relationship between the size of the treatment ef-
fect and the change in BNP values was investigated by
plotting the ratio of change in BNP values (calculated
using the formula below) against the hazard rate for
each study with data available.
exp ln median BNP at end of follow−up in BNP−guided therapy groupð Þ− ln median BNP at baseline in BNP−guided therapy groupð Þf g
exp ln median BNP at end of follow−up in symptom−guided therapy groupð Þ− ln median BNP at baseline in symptom−guided therapy groupð Þf g
For the three studies providing IPD data, the ratio of
change was also calculated using the patient-specific
change from baseline; after logarithmic transformation
of all BNP values, the median change from baseline was
calculated in each treatment group, and the ratio of the
exponents of medians was calculated. All but two aggre-
gate data studies provided median BNP values in their
published report. For the two that did not (Christchurch
Pilot and Signal-HF), we used the summary statistic re-
ported (see Table 3). All analyses were conducted using
Stata, v14.0, using the ‘ipdmetan’ command [18].
Sensitivity analysis
The following sensitivity analyses were conducted:
restricting the analysis to RCTs that defined a BNP tar-
get; and restricting the analysis to RCTs with good allo-
cation concealment, since this has been shown to be an
important source of bias in RCT.
Checking for publication and data availability bias
Funnel plots were used to investigate association be-
tween the precision of the effect size and effect size
(which could be due to publication bias or ‘small study
effects’) [19], including and excluding RCTs for which
IPD were unavailable. We included funnel plots only if a
sufficient number of studies (more than 10) were avail-
able for each outcome.
Results
Figure 1 shows the flow of studies through the review
process. Full-text screening of 70 articles and unpub-
lished studies identified 19 studies eligible for inclusion
for which IPD were requested. Of these, 14 studies were
included in the meta-analysis (5 IPD and 9 aggregate).
Table 1 shows the characteristics of the included
RCTs. Of the 14 RCTs included in the meta-analysis,
eight were conducted in Europe [20–27], two in New
Zealand [28, 29], three in North America [11, 30, 31],
and one in Israel [32]. One RCT (Time-CHF) published
results separately for HFrEF [26] and HFpEF [33]. Only
one RCT [25] (Signal-HF, Sweden) was conducted in pri-
mary care; the other 13 were conducted in hospital HF
clinics, with most of these recruiting patients during or
immediately after hospitalisation for HF. Twelve RCTs
used a BNP-lowering strategy [11, 20–26, 28–31] and
two used a BNP-monitoring strategy [27, 32]. Of the 12
RCTs that used a BNP-lowering strategy, nine set a single
target (BNP 100–300 pg/ml; NT-proBNP 400–2200 pg/ml
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[11, 20, 21, 23, 24, 26, 28–30]), two of which used
age-stratified (< 75 years and ≥ 75 years [24, 26]) targets,
and three set an individual BNP target (BNP level at dis-
charge, reduction of 50% from baseline [22, 25, 31]). Algo-
rithms for modifying treatment in the BNP-guided therapy
groups differed slightly between RCTs, but all were based on
stepwise titration of therapy according to clinical guidelines.
Treatment for symptom-guided therapy groups used an al-
gorithm designed to achieve a target HF score based on signs
and symptoms (e.g. Framingham HF score and NYHA class)
in five RCTs [20, 26, 28, 29, 31] and was entirely at the clini-
cian’s discretion in seven RCTs [11, 21–25, 30].
In the IPD dataset, the mean age of participants was
70 years, three quarters of patients were men, most pa-
tients had LV systolic dysfunction (median LVEF, 30%)
and over 80%) had NYHA class II or III (Table 2). The
patients in RCTs providing aggregate data had similar
characteristics (Table 3).
Eleven out of the 14 included RCTs (79%) were rated
as having a high risk of bias across at least one risk
domain (Additional file 2: Appendix 2). The main factor
that contributed to ratings of high risk of bias was the
lack of blinding (of participants and care-giving
clinicians). None of the funnel plots generated for the
Fig. 1 PRISMA flow diagram
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outcomes with more than 10 studies contributing data
suggested marked asymmetry (Additional file 3: Appen-
dix 3). There were no significant issues identified with
the IPD datasets provided. The overall quality of the
body of evidence for all outcomes varied from low to
very low (Table 4).
Primary outcome
Across 13 RCTs that reported all-cause mortality, 17%
(320/1845) of patients in the BNP-guided therapy
group, and 20% (367/1846) of patients in the
symptom-guided therapy group died during follow up.
Median follow-up in the five RCTs that provided IPD
was 18 months (IQR 8–27). BNP-guided therapy did
not reduce the hazard of death from any cause com-
pared with symptom-guided therapy (HR 0.87, 95%
CI 0.75 to 1.01) (Fig. 2). There was no significant
heterogeneity between RCTs. The sensitivity analysis
excluding the two RCTs that did not use a
BNP-lowering strategy did not alter this finding (HR
0.86, 95% CI 0.73 to 1.01). The sensitivity analysis
combining the effect estimates from three RCTs that
were judged to have had good allocation concealment
showed no difference in the hazard of death between
groups (HR 0.93, 95% CI 0.60–1.44).
Secondary outcomes
Five RCTs provided aggregate data on numbers of
patients with cardiovascular death; these showed that
12% (120/963) of patients in the BNP-guided therapy group
and 14% (130/946) of patients in the symptom-guided
therapy group died because of a cardiovascular cause.
BNP-guided therapy did not reduce the odds of cardiovas-
cular death (OR 0.88, 95% CI 0.66–1.16) (Fig. 3). Only two
studies provided aggregate data on death due to HF;
Stars-BNP [23] and Upstep [24] showed that 3% (3/110)
and 15% (21/140), respectively, of patients in the
BNP-guided therapy group, and 8% (9/110) and 12.5%
(16/128), respectively, of patients in the symptom-guided
therapy group had a death directly attributable to HF.
Across six RCTs with data on all-cause hospitalisa-
tion, 58% (285/493) of patients in the BNP-guided
therapy group had at least one hospital admission,
compared with 57% (281/491) of patients in the
symptom-guided therapy group. BNP-guided therapy
did not reduce the hazard of all-cause hospitalisation
(HR 0.97, 95% CI 0.85–1.10) (Fig. 4). The results did
not differ in the analysis restricted to RCTs that used
a BNP-lowering strategy (HR 0.95, 95% CI 0.81–1.11).
Across eight RCTs that provided data on numbers of
patients with HF hospitalisation, there were 392/1328
patients (29.5%) who had at least one hospitalisation for
HF in the BNP-guided therapy group, compared with
452/1327 patients (34%) in the symptom-guided therapy
group. BNP-guided therapy led to a lower hazard of hos-
pitalisation due to HF (HR 0.81, 95% CI 0.68–0.98)
(Fig. 5). The results did not differ in the sensitivity ana-
lysis restricted to RCTs that set a BNP target (HR 0.77,
95% CI 0.64–0.99). The sensitivity analysis with respect
to allocation concealment was not performed because
only two RCTs were classified as having a low risk of bias.
In all meta-analyses (for primary and secondary out-
comes), the results from the fixed-effects meta-analyses
did not differ from the random-effects meta-analyses
results.
Subgroup analyses
Stratum-specific treatment effects are reported in
Additional file 4: Appendix 4. For all-cause mortality,
there was a significant interaction between treatment
strategy and age (p = 0.034, 11 RCTs), and treatment
strategy and LVEF (p = 0.026, 10 RCTs). BNP-guided
therapy was beneficial for trial participants < 75 years
old (HR 0.70, 95% CI 0.53–0.92) but not for trial par-
ticipants ≥ 75 years old (HR 1.07, 95% CI 0.84–1.37).
Similarly, BNP-guided therapy was beneficial for trial
participants with HFrEF (HR 0.84, 95% CI 0.71–0.99),
but not those with HFpEF (HR 1.33, 95% CI 0.83–
2.11). This effect was largely driven by one RCT
(Time-CHF); excluding this from the analysis attenu-
ated the protective effect in the lower LVEF subgroup
was attenuated (HR 0.89, 95% CI 0.73–1.06).
There were no significant interactions between treatment
strategy and any of the other covariates investigated in the
subgroup analyses for any of the outcomes (p > 0.05). How-
ever, for age and LVEF, stratum-specific estimates for the
secondary outcomes (all-cause and HF hospitalisations)
were consistent with those for all-cause mortality, suggest-
ing a protective effect of BNP-guided therapy.
Changes in BNP from baseline to end of follow-up
BNP levels at baseline and end of follow-up were avail-
able for nine RCTs (Table 3). In six of these [11, 22, 25,
28–30], BNP levels decreased in both the BNP-guided
therapy group and the symptom-guided therapy group.
There was no consistent relationship between the
change in BNP from baseline between groups and the
HR for all-cause mortality (Fig. 6). RCTs that provided
evidence for a relationship (i.e. studies with the most ex-
treme HRs for mortality favouring BNP guided-therapy
and in which BNP fell substantially more in the
BNP-guided group than in the symptom-guided group)
provided least weight in the meta-analysis. Calculating
the relative change between groups using IPD (for stud-
ies that provided IPD) provided even less evidence for a
relationship.
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Fig. 3 Cardiovascular mortality. Odds ratio (OR) with 95% confidence intervals (CI) for five aggregate data studies. Note: weights are from random
effect analysis
Fig. 2 All-cause mortality. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD, aggregate data, and
overall. Time-CHF reported results separately for patients with heart failure with reduced ejection fraction (HFrEF) [26] and patients with heart
failure with preserved ejection fraction (HFpEF) [33]. HR for all-cause mortality was not available for the Protect study [30]. The HR and 95% CI
from Guide-It [11] was adjusted for age, sex, left ventricular ejection fraction, NT-proBNP, and the presence of diabetes mellitus. Note: weights are
from random effect analysis
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Medication changes
We could not combine IPD and aggregate data to inves-
tigate the association between changes in medication
and outcomes because changes in medication were in-
consistently reported in studies on both IPD studies and
aggregate data studies.
Adverse events and discontinuation
None of the IPD studies provided data on adverse events.
Five aggregate data studies [11, 25, 26, 29, 30, 33] provided
data on total number of adverse events by group; these
showed that 29% (293/1023) of patients in the BNP-guided
therapy group and 14% (130/946) of patients in the
symptom-guided therapy group experienced an adverse
event. Adverse events were significantly more frequent in the
BNP-guided therapy group compared with that in
symptom-guided therapy group (OR 1.29, 95% CI 1.04 to
1.60) (Fig. 7). Adverse events most commonly reported
included renal impairment and hypotension, one study re-
ported additional adverse events such as hyper/hypokal-
aemia, anaemia, fever, dizziness, gastrointestinal bleeding,
respiratory infection, and syncope.
Quality of life (QoL)
None of the IPD studies provided QoL data both at base-
line and follow-up. QoL data were available from aggre-
gate data in six studies (including the published reports of
two IPD studies: Northstar [27] and Upstep [24]). These
could not be pooled in a meta-analysis because changes in
QoL were reported differently in each study. Five studies
assessed QoL using the Minnesota Living with Heart
Failure questionnaire [22, 26–28, 30], and one study [24]
assessed QoL using the SF-36 questionnaire. Northstar [27]
reported no change in QoL in either group [median (IQR)
change 0 (− 6 to 2) and 0 (− 5 to 6) between baseline and
end of study visit (6 months to 4.5 years), in the
BNP-guided therapy group and symptom-guided therapy
group, respectively]. Three of the aggregate data studies
showed that QoL improved significantly and similarly in
both groups: Battlescarred [28]: mean (SD) 36.5 (22.7) and
36.6 (23.1) at baseline vs. 28.8 (21.6) and 26.5 (22.0) at
12 months in the BNP-guided therapy group and
symptom-guided therapy group, respectively; Prima [22]
(median (IQR), 47 (34 to 62) and 48 (36 to 60) at baseline
vs. 20 (3–36) and 23 (10–38) at 12 months follow up, in
the BNP-guided therapy group and symptom-guided ther-
apy group, respectively; Time-CHF [26] (mean (SD), 38.3
(20.2) and 40.2 (20.3) at baseline vs. 27.7 (17.90 and 27.0
(18.6) at 12 months, in the BNP-guided therapy group and
symptom-guided therapy group, respectively. Only one of
the aggregate data studies showed a greater improvement
in the BNP-guided therapy group compared with the
symptom-guided therapy group [Protect [30] (median im-
provement between baseline and follow-up at 12 months,
− 10.0 vs. − 5.0, p = 0.05, in the BNP-guided therapy group
and symptom-guided therapy group, respectively]. The
Upstep study [24] assessed quality of life using the SF-36
questionnaire (eight domains) and found no significant
Fig. 4 All-cause hospitalisation. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD, aggregate data,
and overall. HR for all-cause hospitalisation was only available for Time-CHF (HFrEF and HFpEF [33]). Note: weights are from random
effect analysis.
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differences between groups [34]. The remaining studies did
not provide data on QoL; three studies included a state-
ment to say that the change/improvement in QoL was
similar in both groups [20, 25, 29], one study did not men-
tion quality of life [31], while the Guide-It study included a
statement saying that the results of QoL analyses were not
reported in their manuscript [11].
Discussion
Main findings
Our meta-analysis, including data for up to 3968 pa-
tients with HF (1982 randomised to BNP-guided therapy
and 1986 randomised to symptom-guided therapy)
suggests that BNP-guided therapy may result in little to
no difference in all-cause or cardiovascular mortality. It
is uncertain whether BNP-guided therapy reduces hos-
pital admissions for HF because the quality of evidence
is very low. BNP-guided therapy may lead to an increase
in adverse events. A previous IPD meta-analysis by
Troughton et al. [9] (which excluded the subgroup of
participants with HFpEF from the Time-CHF RCT)
showed a 18% reduction in the hazard of death from any
cause (HR 0.82, 95% CI 0.67–1.00) and a 26% reduction
in the hazard of hospital admission for HF (HR 0.74,
95% CI 0.60–0.90), but the authors did not assess the
quality of evidence and therefore reached different con-
clusions. The results from our subgroup analyses
showed more benefit of BNP-guided therapy in patients
< 75 years old and patients with HFrEF, which is consist-
ent with the analyses reported by Troughton et al. [9]
and Brunner La-Rocca et al. [17].
Was the treatment effect a result of decreasing BNP or
up-titration of medication?
The observed benefit in the BNP-guided therapy group
could not be attributed to changes in BNP levels during
follow-up between groups (Fig. 5). There was no consist-
ent relationship between the relative BNP change from
baseline between groups and the hazard ratio for
all-cause mortality. Although the smaller RCTs showed a
relatively large BNP change between groups and lower
hazard ratios, this was not reflected in the larger RCTs
that provided most weight in the meta-analysis. The
meta-analysis by Troughton et al. [9] showed that BNP
levels decreased by 35% in the BNP-guided therapy
group and 32% in the symptom-guided therapy group.
Fig. 5 Heart failure (HF) hospitalisation. Unadjusted individual hazards ratios (HR) with 95% confidence intervals (CI) presented within IPD,
aggregate data, and overall. Note: weights are from random effect analysis
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Similarly, the Guide-IT RCT showed a 53% decrease in
the BNP-guided therapy group and a 48% decrease in
the symptom-guided therapy group.
Although we could not determine whether and how HF
medication doses changed during follow up, the
meta-analysis by Troughton et al. [9] showed no differences
in medication dose changes between groups, except for a
modest increase in doses of angiotensin-converting enzyme
inhibitors (ACEi)/angiotensin II receptor blockers (ARB) in
the BNP-guided therapy group (8.4% increase, 3.4 to 13, vs.
− 1.2% decrease, − 6.1 to 3.7 in the symptom-guided
therapy group). While treatment with ACEi and ARB
according to guidelines has been shown to reduce the risk
of death and hospitalisation in both RCTs and large
registries [35–38]; over 89% of patients in the RCTs were
already receiving these medications [9], so it is unclear
whether the relatively small dose increases in the
BNP-guided therapy group were responsible for the benefit
Fig. 7 Total adverse events. Odds ratios (OR) and 95% confidence intervals (CI) for five aggregate data studies. Note: weights are from random
effect analysis
Fig. 6 Relationship between hazard ratios (HR) for all-cause mortality and the ratio of change in BNP/NT-proBNP from baseline between the BNP-
guided therapy group and symptom-guided therapy group. Filled circles represent the ratio of the change calculated using aggregate data, and
open circles represent the ratio of the change calculated using IPD; the change in the position on the x-axis shows the differences between the
two analyses methods, while the position on the y-axis remains the same
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observed. Furthermore, the Guide-IT RCT showed modest
intensification of HF medications, including ACEi and
ARB, in both groups.
BNP-lowering vs. BNP-monitoring strategy
In our meta-analysis, we included all RCTs that used
serial BNP measurements to guide HF therapy, regard-
less of the guiding strategy used. There were several rea-
sons for this. First, we aimed to provide realistic
treatment effect estimates given that, in the absence of
established guidelines describing how treatment should
be guided by BNP, clinicians are likely to use BNP levels
to manage their patients in diverse ways (e.g. to check
the status quo, to lower BNP as much as possible, or to
a target). Second, the two strategies are not fundamen-
tally dissimilar, since both will prompt a patient review
with intensification of medications if considered appro-
priate. Third, RCTs evaluating BNP-lowering were them-
selves heterogeneous in design, treatment strategies (in
both the BNP group and the control group), and BNP tar-
get. Finally, we wished to include all studies in order to
avoid publication related biases, data availability bias, and
reviewer selection bias [39–41]; previous meta-analyses did
not publish a priori protocols. These biases can lead to
meta-analyses being biased towards more favourable treat-
ment effects [41, 42] and have been highlighted as a poten-
tial problem in meta-analyses that use IPD [41]. The
exclusion of two studies that did not target a specific BNP
level [27, 32] did not alter the findings of our meta-analysis.
Strengths and limitations of this study
Our meta-analysis has several strengths. We systematically
identified all RCTs evaluating BNP-guided therapy in HF
patients, included all RCTs for which IPD or aggregate
data were available, and conducted meta-analyses in ac-
cordance with a pre-specified protocol [12] and published
guidelines. There was no evidence of publication bias or a
small study effect (for all-cause mortality and HF hospital-
isation, which had data from more than 10 studies).
The main limitation was our inability to obtain IPD
from most of the RCTs included in the meta-analysis by
Troughton et al. [9], which constrained our sub-group
analyses. Other limitations arose from the design of the
RCTs: heterogeneity in how BNP-guided therapy and
symptom-guided therapy was administered; restricted
eligibility (mainly younger patients with HFrEF and
without co-morbidities), limiting the applicability of the
results to the broader HF population; and the poten-
tial for bias because most RCTs did not blind clini-
cians or patients to treatment allocation. This lack of
blinding means that co-interventions affecting out-
comes could have been initiated by either the doctors
or the participants themselves, conditional on their
knowledge of the allocation. Also, despite combining
results from 14 RCTs, the pooled sample size (up to
3968 patients with HF) was relatively small in com-
parison with sample sizes in other meta-analyses in
this patient population (some of which included over
13,000 patients [43]); therefore, chance may explain
some of the apparently significant findings. Finally,
data on adverse events were not reported consistently
and therefore only five studies contributed data for a
meta-analysis.
Implications for clinicians and policy-makers
Our meta-analysis has shown that BNP-guided treat-
ment in hospital cardiology clinics significantly reduced
HF hospitalisation but not all-cause or cardiovascular
mortality. However, this conclusion may not be applic-
able to other health settings and HF patients who were
not eligible (older patients with HFpEF). By contrast,
across many European countries, cardiologists do not
lead the management of patients with HF, and about half
of all patients have HFpEF. Patients with HFpEF tend to
be older with more comorbidities than their HFrEF
counterparts. There are significant gaps and variation in
the medical care of HF patients, and there is evidence
that not all patients are receiving optimal treatment ac-
cording to guidelines [44]. It therefore appears more
prudent in the first instance to ensure adherence to
guidelines for managing HF before recommending
BNP-guided therapy.
Conclusion
The conclusions about the efficacy of BNP-guided
therapy are uncertain because the findings are of bor-
derline statistical significance and the overall quality
of the evidence varied from low to very low. We
could not identify an optimal BNP monitoring strat-
egy and no group of researchers has defined one.
Therefore, consensus about an optimal BNP monitor-
ing strategy should urgently be sought, preferably
through a formal process involving cardiologists, gen-
eral practitioners, and patients. It is striking that BNP
levels decreased, and HF medications increased in
both the BNP-guided therapy and symptom-guided
therapy groups in the RCTs; this strongly suggests
that HF management outside the RCTs was subopti-
mal. The reasons why not all patients receive care ac-
cording to guidelines is unclear; understanding why
may require qualitative research with different types
of practitioner who care for HF patients.
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